Skip to main content
Journal cover image

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.

Publication ,  Journal Article
Boonen, S; Black, DM; Colón-Emeric, CS; Eastell, R; Magaziner, JS; Eriksen, EF; Mesenbrink, P; Haentjens, P; Lyles, KW
Published in: J Am Geriatr Soc
February 2010

OBJECTIVES: To determine the efficacy of once-yearly intravenous zoledronic acid (ZOL) 5 mg in reducing risk of clinical vertebral, nonvertebral, and any clinical fractures in elderly osteoporotic postmenopausal women. DESIGN: A post hoc subgroup analysis of pooled data from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly (HORIZON) Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial. SETTING: Multicenter, randomized, double-blind, placebo-controlled trials. PARTICIPANTS: Postmenopausal women (aged > or =75) with documented osteoporosis (T-score < or =-2.5 at femoral neck or >/=1 prevalent vertebral or hip fracture) or a recent hip fracture. INTERVENTION: Patients were randomized to receive an intravenous infusion of ZOL 5 mg (n=1,961) or placebo (n=1,926) at baseline and 12 and 24 months. MEASUREMENTS: Primary endpoints were incidence of clinical vertebral and nonvertebral and any clinical fracture after treatment. RESULTS: At 3 years, incidence of any clinical, clinical vertebral, and nonvertebral fracture were significantly lower in the ZOL group than in the placebo group (10.8% vs 16.6%, 1.1% vs 3.7%, and 9.9% vs 13.7%, respectively) (hazard ratio (HR)=0.65, 95% confidence interval (CI)=0.54-0.78, P<.001; HR=0.34, 95% CI=0.21-0.55, P<.001; and HR=0.73, 95% CI=0.60-0.90, P=.002, respectively). The incidence of hip fracture was lower with ZOL but did not reach statistical significance. The incidence rate of postdose adverse events were higher with ZOL, although the rate of serious adverse events and deaths was comparable between the two groups. CONCLUSION: Once-yearly intravenous ZOL 5 mg was associated with a significant reduction in the risk of new clinical fractures (vertebral and nonvertebral) in elderly postmenopausal women with osteroporosis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Geriatr Soc

DOI

EISSN

1532-5415

Publication Date

February 2010

Volume

58

Issue

2

Start / End Page

292 / 299

Location

United States

Related Subject Headings

  • Zoledronic Acid
  • Spinal Fractures
  • Randomized Controlled Trials as Topic
  • Osteoporosis
  • Medication Adherence
  • Infusions, Intravenous
  • Imidazoles
  • Humans
  • Geriatrics
  • Fractures, Spontaneous
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boonen, S., Black, D. M., Colón-Emeric, C. S., Eastell, R., Magaziner, J. S., Eriksen, E. F., … Lyles, K. W. (2010). Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc, 58(2), 292–299. https://doi.org/10.1111/j.1532-5415.2009.02673.x
Boonen, Steven, Dennis M. Black, Cathleen S. Colón-Emeric, Richard Eastell, Jay S. Magaziner, Erik Fink Eriksen, Peter Mesenbrink, Patrick Haentjens, and Kenneth W. Lyles. “Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.J Am Geriatr Soc 58, no. 2 (February 2010): 292–99. https://doi.org/10.1111/j.1532-5415.2009.02673.x.
Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010 Feb;58(2):292–9.
Boonen, Steven, et al. “Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.J Am Geriatr Soc, vol. 58, no. 2, Feb. 2010, pp. 292–99. Pubmed, doi:10.1111/j.1532-5415.2009.02673.x.
Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010 Feb;58(2):292–299.
Journal cover image

Published In

J Am Geriatr Soc

DOI

EISSN

1532-5415

Publication Date

February 2010

Volume

58

Issue

2

Start / End Page

292 / 299

Location

United States

Related Subject Headings

  • Zoledronic Acid
  • Spinal Fractures
  • Randomized Controlled Trials as Topic
  • Osteoporosis
  • Medication Adherence
  • Infusions, Intravenous
  • Imidazoles
  • Humans
  • Geriatrics
  • Fractures, Spontaneous